Plaque psoriasis spray gets go-ahead from US FDA

A topical spray for psoriasis has been approved for a new drug application.

A topical spray for the treatment of plaque psoriasis has been approved for a new drug application by the US Food and Drug Administration.
Taro Pharmaceutical Industries revealed its Topicort (desoximetasone) Topical Spray at 0.25 per cent has been given the go-ahead by the US regulator.
It is a corticosteroid used for the treatment of plaque psoriasis in sufferers aged 18 and older, with the corticosteroid spray market said to be worth $100 million in the US.
Plaque psoriasis, otherwise known as psoriasis vulgaris, is the most prevalent form of the disease, making up around 80 per cent of all cases of psoriasis.
It is characterised by inflamed red lesions that appear on the skin and which are covered by a silvery-white scale. Patients tend to see it erupt on their elbows, scalp, knees and lower back.
Taro Pharmaceuticals was first established by a partnership between Israeli and American physicians led by Levitt and Moros in 1950.